Streetbeat News

Stock Prices

ALDX

Aldeyra Therapeutics shares are trading higher after the company achieved the primary endpoint in its Phase 3 trial for Reproxalap ophthalmic solution in treating dry eye disease. The company anticipates resubmitting its NDA in 2024.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:20 am

APLS

Apellis Pharmaceuticals and Sobi announced positive Phase 3 VALIANT study results for Pegcetacoplan in treating rare kidney diseases, achieving a 68% reduction in proteinuria. The results were consistent across all subgroups, and data submission is planned for the US and EU. Apellis will host a conference call at 8:00 AM ET.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:20 am

SUP

Superior Industries International has updated its FY24 outlook, lowering its net sales forecast to $1.35B-$1.41B from the prior $1.38B-$1.48B, citing lower aluminum costs and reduced production volumes by OEMs. Adjusted EBITDA and Value-Added Sales forecasts were also lowered, while Unlevered Free Cash Flow estimates remain unchanged. Capital expenditures are expected to be around $40 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:20 am

AGEN

Agenus (NASDAQ:AGEN) reported Q2 2024 GAAP EPS of $(2.52), missing the $(1.07) estimate by 135.51%. Sales were $23.509M, missing the $61.477M estimate by 61.76%. EPS improved by 35.88% YoY, while sales decreased by 7.06% YoY.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:19 am

GDRX

GoodRx Holdings shares are trading lower after the company reported worse-than-expected Q2 adjusted EPS results and issued Q3 revenue guidance below estimates.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:19 am

UHG

United Homes Gr (NASDAQ:UHG) reported a significant increase in Q2 earnings per share (EPS) to $0.50, up 614.29% from $0.07 YoY. Sales also rose by 15.39% to $109.42 million from $94.83 million YoY.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:18 am

SN

SharkNinja shares are trading higher after the company reported better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:17 am

TKO

TKO Group Holdings (NYSE:TKO) reported Q2 2024 earnings per share (EPS) of $0.72, missing the analyst estimate of $0.91 by 20.88%. However, the company reported sales of $851.2 million, beating the estimate of $771.313 million by 10.36%. This represents a 178.90% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:17 am

SRRK

Scholar Rock Holding (NASDAQ:SRRK) reported a Q2 2024 GAAP EPS of $(0.60), which met the analyst consensus estimate.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:16 am

ECX

ECARX Holdings (NASDAQ:ECX) reported Q2 2024 GAAP EPS of $(0.12), missing the $(0.08) estimate, but achieved sales of $173.000M, beating the $169.746M estimate. EPS decreased by 71.43% year-over-year, while sales increased by 31.66%.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:16 am